ARTICLE | Company News
Roche, Areva deal
July 30, 2012 7:00 AM UTC
Areva's Areva Med LLC (Bethesda, Md.) subsidiary partnered with Roche to create an alpha radio-immunotherapy platform to treat cancer. Roche's Pharma Research & Early Development organization (pRED) will assess the efficacy of combining Roche-engineered antibodies with Areva's radionuclide, Lead-212. Roche will retain exclusive commercialization rights to the radio-immunotherapy following clinical development. Details were not disclosed. ...